Is West Nile virus a potential cause of central nervous system infection in Brazil?

Cristiane N. Soares¹,2, Mauro J. Cabral Castro²,3, José M. Peralta³, Marcos R.G. de Freitas¹, Marzia Puccioni-Sohler²,4

ABSTRACT
Meningitis and encephalitis are complications of West Nile virus (WNV) infection. Although WNV is endemic in North America, the virus has recently been reported in Colombia and Argentina. Investigation of WNV in Brazil is important since this virus has never been studied previously in this country. Objective: To investigate the presence of WNV infection in viral encephalitis/meningitis cases of unknown etiology in the city of Rio de Janeiro, Brazil. Method: Thirty-seven adults with viral meningitis/encephalitis had their serum and CSF tested for WNV antibodies using the ELISA method. Results: Only one case was WNV-positive, but this case was also positive for dengue. The plaque reduction neutralization test distinguished infections, and was negative for WNV. Conclusion: WNV can be confused with dengue infection. Their symptoms and neurological picture are similar. We did not find WNV in any patients with encephalitis and meningitis in the city of Rio de Janeiro. Up to now, it has not been detected in Brazil.

Key words: viral, meningitis, encephalitis, dengue infection, West Nile virus, CSF.

Seria o vírus do Oeste do Nilo causa potencial de infecção no sistema nervoso central no Brasil?

RESUMO

Palavras-chave: viral, meningite, encefalite, dengue, vírus do Oeste do Nilo, líquido cefalorraquidiano.

West Nile virus (WNV) infection is caused by a flavivirus, a member of the Japanese encephalitis virus serocomplex. It was first isolated from an infected person in Uganda, in 1937. From 1937 to 1990, the virus was responsible for in-
frequent human outbreaks in Israel and Africa. However, since the mid-1990s, the frequency and severity of WNV outbreaks have increased. Since detection of the virus in New York City in 1999, it has caused more than 16,000 cases of human disease and more than 660 deaths in North America. The virus is transmitted by the bite of an infected mosquito, and it infects birds, humans and equines equally. Mosquitoes become infected in late summer and then pose an infection threat to humans and birds. Consequently, tropical areas have great potential for transmission of the disease. The clinical picture can vary from subclinical infection to an illness that is usually characterized by fever, malaise, anorexia, nausea, vomiting, headache and myalgia, and it may last for three to seven days. A macular, papular or morbilliform exanthem is also seen.

Neurological manifestations, including encephalitis and meningitis, are complications of WNV infections, in the same way as in dengue infection. Encephalitis is the most common neurological manifestation. In West Nile infection, meningitis and encephalitis may develop in approximately one in 150 infected individuals. The clinical features of this neurological infection include diffuse flaccid paralysis, resembling Guillain-Barré syndrome (GBS), but with characteristics that would be unusual for this disease (pleocytosis on CSF and axonal and demyelinat

sles on electromyography). More rarely, ataxia and extrapyramidal signs, cranial nerve abnormalities, myelitis, optic neuritis, and polyradiculitis can be observed in WNV infection.

The aim of the study was to search prospectively for the presence of West Nile antibodies in patients presenting with viral encephalitis or meningitis in Rio de Janeiro, Brazil. South America receives hundreds of migratory bird species from the Northern Hemisphere, many from areas where the virus has been detected. In addition, Rio de Janeiro is a tourism center that receives people from all over the world and is in a tropical area where mosquito proliferation occurs. These factors make this city a potential area for a WNV epidemic.

METHOD

This study was prospective. We selected 37 immunocompetent adult patients with clinical diagnoses of viral meningitis or encephalitis who were seen in two hospitals in the city of Rio de Janeiro (Hospital de Clínicas de Niterói and Hospital Quinta D’or), between March 2006 and March 2008. We analyzed age, sex, clinical signs and symptoms on admission and CSF profile, and we looked for WNV antibodies in the CSF and serum. The study protocol was approved by the Ethics Committees of both hospitals, and all patients signed the informed consent form.

Clinical diagnosis

The criteria for acute meningitis included: [A] acute (<3 weeks’ duration) onset of symptoms such as headache, fever and nuchal rigidity; [B] CSF parameters (cell count >5 cells/mm³, glucose ratio >45 mg/dl and negative bacteriological/fungal investigations).

The patients were diagnosed as having encephalitis if they had fever and acutely altered consciousness/personality, seizures or focal neurological signs. A normal cell count on CSF did not rule out the diagnosis of encephalitis, since there have been reports that it can be normal in 5% of such cases, but all bacteriological and fungal cultures had to be negative. All patients underwent spinal tap on the day of admission and their serum was collected at the same time.

Laboratory assays

Routine CSF analysis – Routine CSF analysis was performed in a reference CSF laboratory (Neurolife) located in Rio de Janeiro. The total cell count was determined using a Fuchs-Rosenthal chamber, and differential cytology was determined by means of cell sedimentation. The CSF protein and glucose levels were analyzed by spectroscopy. Immunological tests were performed for syphilis (VDRL), HTLV-1 (human T-cell leukemia virus-1), Herpes simplex, Varicella zoster, cytomegalovirus and HIV1/2 antibodies (enzyme-linked immunosorbent assay - ELISA), and bacterial and fungal cultures were produced.

Screening for IgM antibodies for WNV – The CSF and serum of all patients were screened for anti-WNV antibodies using ELISA (PANBIO, Brisbane, Australia). The serum was diluted (1:100) in accordance with the manufacturer’s recommendation. In order to increase the sensitivity of the test for CSF, it was diluted (1:2). The WNV ELISA test on CSF has a sensitivity of 95% and specificity of approximately 92.4%.

Laboratory criteria for WNV positivity – WNV was diagnosed by the presence of anti-WNV IgM in the serum or CSF. If the immunological tests were positive for WNV, the tests were repeated and dengue IgM antibody was tested because of possible cross-reaction. The plaque reduction neutralization test for WNV was performed when there were positive tests for WNV and dengue virus.

RESULTS

Thirty-seven patients fulfilled the criteria: 20 patients for viral meningitis and 17 for viral encephalitis. There were 12 males and eight females with a diagnosis of meningitis, with an average age of 32.2 years (standard deviation of ±12.5 years). All patients presented headache. Vomiting were present in 50% of the cases and nuchal rigidity in 55%. The average CSF pleocytosis was 169 cells/mm³. In West Nile virus Brazil Soares et al. Arq Neuropsiquiatr 2010;68(5)
(standard deviation of ±176.8 cells/mm³) and high CSF protein levels were found in 80% of the cases (average of 65 mg/dl and standard deviation of ±34.6 mg/dl).

The average age of the patients with encephalitis was 48.7 years (standard deviation of ±27.6 years) and the male/female ratio was 12/5. The commonest symptom was seizures (70.5%). Altered consciousness and headache were each present in 58.8% of the cases. Focal neurological signs/symptoms were present in four patients. The average cellularity in CSF in this group was 20.7 cells/mm³ (standard deviation of ±34.7 cells/mm³), and high CSF protein levels were found in 52.9% of the cases (average of 49.5 mg/dl and standard deviation of ±31.1 mg/dl).

One case of encephalitis had WNV IgM antibodies in the serum, found using the ELISA test. He was 32 years of age and presented fever, myalgia and three episodes of complex partial seizures. The neurological examination was normal. The symptoms lasted four days. Since WNV was positive in the serum, dengue serological tests were performed, which were also positive. However, the plaque reduction neutralization test for WNV (FDA/USA) was used to distinguish serological cross-reactions, and it was negative for WNV.

**DISCUSSION**

WNV is endemic in the USA, with approximately 19,525 cases reported from 1999 to 2007, and 44% of these cases involved neurological impairment. Until recently, WNV had only been seen in isolated reports of cases in Latin America. Between 2001 and 2004, case reports were cited in Mexico, Belize, Guatemala, El Salvador, Cuba, the Bahamas, the Cayman Islands, Jamaica, the Dominican Republic, Trinidad and Tobago, Puerto Rico and Colombia. Recently, WNV was found in Argentina, causing infection in birds and neurological disorders in three horses.

In our country, approximately 97 species of birds migrate from the northern hemisphere, and 18 species perform vertical displacement between southeastern Brazil and the Andes. Because of bird migration and mosquito proliferation, virus monitoring is fundamental in our country, in order to prevent potential virus dissemination.

Only one of our cases of encephalitis was positive for WNV according to ELISA IgM in the serum. The WNV ELISA test was used in spite of the possibility of using PCR and viral culture because of the low sensitivity of these last two tests, which precludes their use as routine screening tests. In addition, detection of IgM antibodies for WNV in serum or CSF is the most efficient method for diagnosing WNV. Our case presented cross-reactivity for dengue and WNV, showing that it can be confused with dengue virus, both clinically and by laboratory methods. WNV was discarded as a diagnosis by the plaque reduction neutralization test. Overall cross-reactivity between the IgM ELISA and flavivirus has been described in 12% of cases. The reasons for the low morbidity and mortality in Latin America are unclear. Some hypotheses include protection by antigenically cross-reactive flavivirus, decreased virulence of the circulating virus, high biodiversity in tropical regions leading to a dilution effect, and low levels of surveillance and diagnostic efforts.

Finally, the most important point in this study is that, for the first time, WNV was investigated in patients who were previously healthy and developed meningitis and encephalitis. With the recent WNV activity in Argentina, it is fundamental to continue to monitor for this virus as an emerging cause of neurological disease in South America. Up to now, it has not been detected in Brazil.

**ACKNOWLEDGEMENTS** – The authors thank Dr Maria Rios from the Food and Drug Administration (FDA, Bethesda, USA) for providing the plaque reduction neutralization test for WNV (FDA/USA). The authors have no competing interest to declare.

**REFERENCES**